Cleaning out

Vical's successful public offering, coupled to Chiron's Betaseron approval last week, may have heightened some optimism for stocks as the summer winds into August and toward Labor Day. But we're still watching with arched eyebrows as biotech trading volumes continue to sink steadily towards the horizon.

Technical analysts reassure us that low volumes are just what you want to see when stocks are hitting bottom and readying a base.